[144] Centessa Pharmaceuticals plc American SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Centessa Pharmaceuticals plc (CNTA) reports a proposed sale of 25,000 common shares through UBS Financial Services on 09/10/2025 on NASDAQ with an aggregate market value of $550,000.00. The shares were acquired and paid for on 09/10/2025 by exercise of a stock option and payment in cash. The filing lists 134,073,436 shares outstanding. The filing also discloses a sale the prior day: 24,792 shares sold on 09/09/2025 for gross proceeds of $495,840.00 by Tia Bush. The filer certifies no undisclosed material adverse information and includes standard Rule 10b5-1/trading-plan language.

Insights

Securities Analyst

TL;DR: Routine Rule 144 notice showing a small insider option exercise and planned sale; immaterial to capitalization.

The filing documents a proposed sale of 25,000 shares (about 0.019% of the stated 134,073,436 shares outstanding), following an exercise of options and same-day cash payment. The transaction appears procedural and compliant with Rule 144; the size relative to outstanding shares suggests negligible dilution or market impact. Prior day sale of 24,792 shares with similar proceeds indicates consecutive liquidity events by related parties. No earnings, debt, or operational disclosures are included, limiting investor inference.

Corporate Governance Expert

TL;DR: Filing reflects standard insider reporting and attestation; raises routine governance transparency points.

This Form 144 provides required public notice of proposed insider sales and an attestation about material nonpublic information, which supports regulatory transparency. The disclosure that the shares were acquired via option exercise and paid in cash is appropriate for tracking insider compensation realizations. The filing does not disclose any 10b5-1 plan adoption date or additional governance context, so reviewers cannot confirm whether sales follow a pre-established trading plan.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services Inc. 11 Madison Ave. 4th Floor New York NY 10010	25000	550000.00	134073436	09/10/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/10/2025	Exercise of Stock Option	Issuer			25000	09/10/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Tia Bush 1 ASHLEY ROAD 3rd Floor Altrincham, Chesire X0 WA14 2DT	Common	09/09/2025	24792	495840.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Centessa (CNTA) disclose?

The Form 144 discloses a proposed sale of 25,000 common shares on 09/10/2025 via UBS on NASDAQ with aggregate market value of $550,000.00.

How were the 25,000 shares acquired according to the filing?

The shares were acquired on 09/10/2025 by exercise of a stock option from the issuer and paid for in cash on that date.

Did the filer report any recent sales of Centessa shares?

Yes. The filing shows that Tia Bush sold 24,792 shares on 09/09/2025 for gross proceeds of $495,840.00.

What is the number of Centessa shares outstanding listed in the filing?

The filing lists 134,073,436 shares outstanding.

Does the filing indicate the presence of material nonpublic information?

The person for whose account the securities are to be sold represents by signing the notice that they do not know any material adverse information that has not been publicly disclosed.